about
Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database studyPrevalence of antibiotic use: a comparison across various European health care data sources.Temporal fluctuations of myocardia high-energy phosphate metabolite with the cardiac cycle.Evaluation of patients' experiences with antidepressants reported by means of a medicine reporting system.Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepinesGenetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs.Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications.Ascertainment of acute liver injury in two European primary care databases.Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe.Case-only designs for studying the association of antidepressants and hip or femur fracture.Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis.Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR).Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures.The IMI PROTECT project: purpose, organizational structure, and procedures.Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project.Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison.Endothelin-1 Increases Susceptibility of Isolated Rat Hearts to Ischemia/Reperfusion Injury by Reducing Coronary FlowRoutinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular diseaseIncidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records DatabasesA Human(e) Factor in Clinical Decision Support SystemsTask-related variations in motoneuronal drive to a human intrinsic hand muscleBio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the catMyocardial high-energy phosphate metabolism in heart transplant patients is temporarily altered irrespective of rejectionDetection of myocardial viability based on measurement of sodium content: A (23)Na-NMR studyContrast-enhanced ultrasonography during liver surgery (Br J Surg 2004; 91: 1165-1167)Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) after Polytrauma: A Rare Syndrome with Major Consequences
P50
Q28543602-0822C529-0D03-4095-B7E9-A30D528827ADQ30979118-C1DF8627-980B-4007-B3ED-54C1C1434AFEQ34479894-B2676C38-0CF8-4B5D-9450-9B7D15C0D134Q36128887-984A4E0C-4F7E-4114-B7BC-7D3CB4B7437DQ37105528-515EBE3C-5F27-4758-9104-DEEA58E7FE7AQ37681549-45EA1FBC-09E3-4556-BE83-BAC08726DF83Q38209071-1BB6B53B-3135-4F85-8194-F99DF943DEFEQ38234453-68534C26-AEF4-4BFB-9D61-1BB272B34133Q38920121-D1CB8712-1EC9-479F-9D83-57AF3FD7A1B2Q38965535-674DD474-E82F-42B3-BB5C-EE988BD1B03FQ39313673-59CEFC5B-4CF9-4388-A223-7B71EB7B7672Q39869497-E70D0127-5764-40E8-835E-0249E2A60AB1Q39869513-6059CE44-A0DE-4034-B3C6-09F8424CDD98Q39869520-BFFE23A2-A981-4CF1-BD18-516CFED7A6DFQ40763565-8F4E3A17-9791-48DE-B00E-D3F6A9CAD57BQ41650125-8885EDFA-57BE-4C99-BB90-2ED4FE08D124Q45814535-100BDBC2-CF56-4F56-B878-075573ADE98FQ57530566-2E02697D-02F2-4748-8DCA-23E803D0B247Q58760189-0A00C1D0-BB28-4F0B-BF98-FA71A3088276Q61068491-8B57AB3F-73B8-4720-AC38-250C6ABE29A9Q62489055-54DB75A8-6F82-4598-ACA4-3867D0A7FFACQ63952381-B55E9781-F4B9-43CA-B586-DFF8123C68ADQ73304889-379569BC-C33F-492F-91FF-74959B4C07CAQ73431751-ADEACBDB-B8B6-4EC5-BA92-045C96DDDC36Q73808449-B2D6203A-6912-4A1A-B425-FB776FD93FEDQ81236841-28DD82DD-5620-410B-8BBC-C0536C410116Q92636881-3A8189D1-1DF7-46F8-879B-F6556BA2C8CF
P50
description
researcher ORCID ID = 0000-0002-5764-5788
@en
wetenschapper
@nl
name
Mark de Groot
@ast
Mark de Groot
@en
Mark de Groot
@es
Mark de Groot
@nl
type
label
Mark de Groot
@ast
Mark de Groot
@en
Mark de Groot
@es
Mark de Groot
@nl
prefLabel
Mark de Groot
@ast
Mark de Groot
@en
Mark de Groot
@es
Mark de Groot
@nl
P1153
7102642748
P31
P496
0000-0002-5764-5788